Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Qianqian Sun, Weiqing Li, Donghua Yang, Peter Ping Lin, Lina Zhang, Huiqin Guo
CONTEXT.—: Most patients with non-small cell lung cancers (NSCLC) are diagnosed at advanced stages. The 5-year survival rate of patients with advanced lung cancer is less than 20%, which makes lung cancer the leading cause of cancer-related deaths worldwide. OBJECTIVE.—: To identify indicators that can predict the prognosis of lung cancer patients. DESIGN.—: To determine the correlation between circulating tumor cells (CTCs), circulating tumor-derived endothelial cells (CTECs), and their subtypes and the prognosis of patients with NSCLC, 80 patients with lung cancer were recruited and 48 patients who met the enrollment criteria were selected in this study...
April 18, 2024: Archives of Pathology & Laboratory Medicine
#22
REVIEW
Qi Zhang, Shaonan Fan, Xiaohong Xu, Shisuo Du, Guangying Zhu, Chaoyang Jiang, Shi-An Xia, Qiwen Li, Qifeng Wang, Dong Qian, Ming Zhang, Han Xiao, Gang Chen, Zhaochong Zeng, Jian He
PURPOSE: The standard treatment schedule for unresectable stage III non-small-cell lung cancer (NSCLC) is chemotherapy with concurrent radiotherapy (60 Gy delivered in 30 fractions), although moderately hypofractionated radiotherapy (Hypo-RT) has also been considered as an alternative strategy. This study aimed to compare the efficacy and toxicity of moderately Hypo-RT with helical TomoTherapy versus conventionally fractionated radiotherapy (Con-RT) in patients with unresectable stage III NSCLC receiving concurrent chemotherapy...
April 15, 2024: International Journal of Radiation Oncology, Biology, Physics
#23
Jana H Mahdi, Baraa AlJardali, Oussama G Nasrallah, Noura El Sayegh, Marwan Zein, Rami W Nasr
INTRODUCTION: Gastric outlet obstruction presents with a range of symptoms which include abdominal pain, early satiety, weight loss and vomiting caused obstruction secondary to tumors from outside the gastrointestinal tract or due to motility disorders. Bladder cancer is rarely associated with Gastric outlet obstruction. It usually presents with painless hematuria and urinary symptoms. Squamous cell carcinoma is a subtype of bladder malignancies that tends to present at a later stage and is associated with poorer prognosis in terms of metastasis and survival...
April 9, 2024: International Journal of Surgery Case Reports
#24
JOURNAL ARTICLE
Jon Zugazagoitia, Handerson Osma, Javier Baena, Álvaro C Ucero, Luis Paz-Ares
Platinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and consistent increase of long-term survival with PD-1 axis inhibition, the magnitude of the benefit from immunotherapy appears lower as compared to other solid tumors. Several immune evasive mechanisms have been shown to be prominently altered in human SCLC, including, among others, T cell exclusion, downregulation of components of the MHC-class I antigen processing and presentation machinery, or upregulation of macrophage inhibitory checkpoints...
April 17, 2024: Clinical Cancer Research
#25
JOURNAL ARTICLE
Melina Peressini, Rosario Garcia-Campelo, Bartomeu Massuti, Cristina Marti, Manuel Cobo, Vanesa Gutiérrez, Manuel Dómine, Jose Fuentes, Margarita Majem, Javier de Castro, Juan Felipe Cordoba, Maria Pilar Diz, Dolores Isla, Emilio Esteban, Enric Carcereny, Laia Vila, Alberto Moreno-Vega, Silverio Ros, Amaia Moreno, Francisco Javier Garcia, Gerardo Huidobro, Carlos Aguado, Victor Cebey-Lopez, Javier Valdivia, Ramon Palmero, Pilar Lianes, Marta Lopez-Brea, Oscar Juan Vidal, Mariano Provencio, Edurne Arriola, Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Angel Nuñez-Buiza, Álvaro Ucero, Susana Hernandez, Fernando Lopez-Rios, Esther Conde, Luis Paz-Ares, Jon Zugazagoitia
BACKGROUND: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small-cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC. PATIENTS AND METHODS: We analyzed tumor samples from 58 ES-SCLC patients enrolled in two multicenter single-arm phase IIIb studies evaluating front-line chemoimmunotherapy in Spain: n=32 from the IMfirst trial, and n=26 from the CANTABRICO trial...
April 17, 2024: Clinical Cancer Research
#26
JOURNAL ARTICLE
Kiratiya Wongkalasin, Yaowarat Matchim, Ruankwan Kanhasing, Sirinya Pimvichai
BACKGROUND: Uncertainty is the inability to define the meaning of illness-related events, which may result in anxiety, depression, poor coping, the self-perception of being a burden and low quality of life. Uncertainty among Thai patients with advanced-stage lung cancer (ASLC) has not been well documented. AIMS: To assess uncertainty in patients with ASLC. METHODS: A cross-sectional survey design was adopted. Data were collected from 60 patients with ASLC at a university hospital...
April 2, 2024: International Journal of Palliative Nursing
#27
JOURNAL ARTICLE
Melinda L Hsu, Mary C Boulanger, Sarah Olson, Cyd Eaton, Laura Prichett, Matthew Guo, Mattea Miller, Julie Brahmer, Patrick M Forde, Kristen A Marrone, Michelle Turner, Josephine L Feliciano
IMPORTANCE: Despite a growing population of survivors of lung cancer, there is limited understanding of the survivorship journey. Survivors of lung cancer experience unmet physical, social, emotional, and medical needs regardless of stage at diagnosis or treatment modalities. OBJECTIVE: To investigate the association of unmet needs with quality of life (QOL) and financial toxicity (FT) among survivors of lung cancer. DESIGN, SETTING, AND PARTICIPANTS: This survey study was conducted at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center thoracic oncology clinics between December 1, 2020, and September 30, 2021, to assess needs (physical, social, emotional, and medical), QOL, and FT among survivors of lung cancer...
April 1, 2024: JAMA Network Open
#28
JOURNAL ARTICLE
Junqiu Liu, Zhaidong Liu, Chunqin Zhao, Yuting Jiao, Baohong Li, Jiaju Shi, Zichao Chen, Zhen Zhang
Exosomal programmed death ligand-1 (ExoPD-L1) is a vital marker of immune activation in the early stages of tumor therapy and it can inhibit anti-tumor immune responses. However, due to the low expression of ExoPD-L1 in cancer cells, it is difficult to perform highly sensitive assays and accurately differentiate cancer sources. Therefore, we constructed a coaxial dual-path electrochemical biosensor for highly accurate identification and detection of ExoPD-L1 from lung cancer based on chemical-biological coaxial nanomaterials and nucleic acid molecular signal amplification strategies...
April 17, 2024: Nanoscale
#29
JOURNAL ARTICLE
Mathilde Marchand, Antonio Gonçalves, François Mercier, Pascal Chanu, Jin Y Jin, Jérémie Guedj, René Bruno
Model-based tumor growth inhibition (TGI) metrics are increasingly used to predict overall survival (OS) data in Phase III immunotherapy clinical trials. However, there is still a lack of understanding regarding the differences between two-stage or joint modeling methods to leverage Phase I/II trial data and help early decision-making. A recent study showed that TGI metrics such as the tumor growth rate constant KG may have good operating characteristics as early endpoints. This previous study used a two-stage approach that is easy to implement and intuitive but prone to bias as it does not account for the relationship between the longitudinal and time-to-event processes...
April 17, 2024: CPT: Pharmacometrics & Systems Pharmacology
#30
JOURNAL ARTICLE
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N D'Alessandro-Gabazza, Esteban C Gabazza, Tetsu Kobayashi
BACKGROUND: Immune checkpoint inhibitors have recently become the standard of care in the first-line treatment of extensive-stage small cell lung cancer. Although immune-related adverse events have been reported to influence prognosis in non-small cell lung cancer patients, few studies have investigated the prognostic value of immune-related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune-related adverse events after first-line treatment with immune checkpoint inhibitor-based chemotherapy for extensive-stage small cell lung cancer...
April 2024: Cancer Medicine
#31
Yun-Sheng Wu, Yu-Ting Chen, Jen-Hao Chuang, Hsien-Chi Liao
BACKGROUND: Fetal adenocarcinoma is a very rare subtype of lung adenocarcinoma. Its incidence ranges from 0.1 to 0.87% among all primary lung neoplasms. Low-grade types tend to appear in the younger generation, and the age ranges from 20 to 50 years with a mean age of around 35 years. Surgical resection is currently the best way to treat fetal adenocarcinoma lung cancer without distant metastasis. CASE REPORT: This is a 56-year-old female who underwent low-dose computer tomography (LDCT) screening during the health examination...
2024: Frontiers in Oncology
#32
JOURNAL ARTICLE
Yanmin Zhang, Gaoming Wang, Qian Zhang, Qian Wang, Jing Luo, Chunhua Ling
OBJECTIVE: The aim of this study is to investigate the clinical value and potential prognostic significance of lung function assessment and Testin expression in non-small cell lung cancer (NSCLC) patients. METHODS: The NSCLC patients were classified into three groups according to lung function: group of normal lung function, group of PRISm (preserved ratio impaired spirometry) (FEV1, forced expiratory volume during the first second < 80% predicted and FEV1/FVC (forced vital capacity) ≥ 70%) and group of COPD (chronic obstructive pulmonary disease) (FEV1/FVC < 70%)...
April 16, 2024: Journal of Cardiothoracic Surgery
#33
Filippo Tommaso Gallina, Marco Chiappetta, Riccardo Tajè, Daniele Forcella, Carolina Sassorossi, Maria Teresa Congedo, Jessica Evangelista, Isabella Sperduti, Filippo Lococo, Federico Cappuzzo, Enrico Melis, Stefano Margaritora, Francesco Facciolo
No abstract text is available yet for this article.
March 15, 2024: Clinical Lung Cancer
#34
JOURNAL ARTICLE
Jessica Donington, Xiaohan Hu, Su Zhang, Yan Song, Ashwini Arunachalam, Diana Chirovsky, Chi Gao, Ari Lerner, Anya Jiang, James Signorovitch, Ayman Samkari
BACKGROUND: Novel neoadjuvant chemoimmunotherapy treatments are being investigated for locally advanced non-small-cell lung cancer (NSCLC), but real-world outcomes for neoadjuvant treatments are poorly understood. This study examined neoadjuvant treatment patterns, real-world event-free survival (rwEFS) and overall survival (OS) in patients with resected, stage II-III NSCLC in the United States (US). METHODS: This retrospective study identified patients in the SEER-Medicare database (2007-2019) with newly diagnosed stage II, IIIA, and IIIB (N2) NSCLC (AJCC 8th edition) treated with neoadjuvant chemo/chemoradiotherapy and resection (index date: neoadjuvant therapy initiation)...
March 22, 2024: Clinical Lung Cancer
#35
JOURNAL ARTICLE
Joline Ingels, Laurenz De Cock, Dieter Stevens, Rupert L Mayer, Fabien Théry, Guillem Sanchez Sanchez, David Vermijlen, Karin Weening, Saskia De Smet, Nele Lootens, Marieke Brusseel, Tasja Verstraete, Jolien Buyle, Eva Van Houtte, Pam Devreker, Kelly Heyns, Stijn De Munter, Sandra Van Lint, Glenn Goetgeluk, Sarah Bonte, Lore Billiet, Melissa Pille, Hanne Jansen, Eva Pascal, Lucas Deseins, Lies Vantomme, Maarten Verdonckt, Ria Roelandt, Thomas Eekhout, Niels Vandamme, Georges Leclercq, Tom Taghon, Tessa Kerre, Floris Vanommeslaeghe, Annemieke Dhondt, Liesbeth Ferdinande, Jo Van Dorpe, Liesbeth Desender, Frederic De Ryck, Frank Vermassen, Veerle Surmont, Francis Impens, Björn Menten, Karim Vermaelen, Bart Vandekerckhove
Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in early stages. Here, we present the results of a phase I clinical trial in which a dendritic cell (DC) vaccine targeting patient-individual neoantigens is evaluated in patients with resected NSCLC. Vaccine manufacturing is feasible in six of 10 enrolled patients. Toxicity is limited to grade 1-2 adverse events. Systemic T cell responses are observed in five out of six vaccinated patients, with T cell responses remaining detectable up to 19 months post vaccination...
April 9, 2024: Cell reports medicine
#36
JOURNAL ARTICLE
Zhaoshuo Diao, Huiyan Jiang
BACKGROUND: Positron emission tomography (PET) is extensively employed for diagnosing and staging various tumors, including liver cancer, lung cancer, and lymphoma. Accurate subtype classification of tumors plays a crucial role in formulating effective treatment plans for patients. Notably, lymphoma comprises subtypes like diffuse large B-cell lymphoma and Hodgkin's lymphoma, while lung cancer encompasses adenocarcinoma, small cell carcinoma, and squamous cell carcinoma. Similarly, liver cancer consists of subtypes such as cholangiocarcinoma and hepatocellular carcinoma...
April 9, 2024: Computers in Biology and Medicine
#37
JOURNAL ARTICLE
Giuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, Emilio Francesco Giunta, Akash Maniam, Shobana Anpalakhan, Shyamika Acharige, Aruni Ghose, Alfredo Addeo
IMPORTANCE: Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non-small cell lung cancer (NSCLC) have reported consistent associations with event-free survival (EFS) and pathologic complete response (pCR) pending longer follow-up for overall survival data. OBJECTIVE: To assess the pooled benefit of ICI-chemotherapy in 2-year EFS and pCR among patients with NSCLC and examine the impact of clinical, pathologic, and treatment-related factors...
April 1, 2024: JAMA Network Open
#38
JOURNAL ARTICLE
Kevin Tran, Daniel Ginzburg, Wei Hong, Ulrike Attenberger, Hyun Soo Ko
BACKGROUND: Lung cancer, the second most common cancer, presents persistently dismal prognoses. Radiomics, a promising field, aims to provide novel imaging biomarkers to improve outcomes. However, clinical translation faces reproducibility challenges, despite efforts to address them with quality scoring tools. OBJECTIVE: This study had two objectives: 1) identify radiomics biomarkers in post-radiotherapy stage III/IV nonsmall cell lung cancer (NSCLC) patients, 2) evaluate research quality using the CLEAR (CheckList_for_EvaluAtion_of_Radiomics_research), RQS (Radiomics_Quality_Score) frameworks, and formulate an amalgamated CLEAR-RQS tool to enhance scientific rigor...
April 16, 2024: European Radiology
#39
JOURNAL ARTICLE
Kwon Joong Na, Young Tae Kim, Jin Mo Goo, Hyungjin Kim
Background Currently, no tool exists for risk stratification in patients undergoing segmentectomy for non-small cell lung cancer (NSCLC). Purpose To develop and validate a deep learning (DL) prognostic model using preoperative CT scans and clinical and radiologic information for risk stratification in patients with clinical stage IA NSCLC undergoing segmentectomy. Materials and Methods In this single-center retrospective study, transfer learning of a pretrained model was performed for survival prediction in patients with clinical stage IA NSCLC who underwent lobectomy from January 2008 to March 2017...
April 2024: Radiology
#40
JOURNAL ARTICLE
Chuang Yang, Tiantian Xuan, Qing Gong, Xin Dai, Chengjun Wang, Rongyu Zhang, Wen Zhao, Jian Wang, Weiming Yue, Jisheng Li
BACKGROUND: Patients with extensive-stage small cell lung cancer (ES-SCLC) have an exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined with etoposide-platinum is recommended as standard first-line therapy. However, which combination pattern is the best still remains unknown. This network meta-analysis was performed to compare the efficacy and safety of currently available patterns including an antiangiogenic agent containing regimen and probed into the most appropriate therapy for patients...
April 16, 2024: Thoracic Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
